Trial Profile
A phase II study of AZD0530 in hormone receptor-negative, metastatic or unresectable, locally Advanced Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Saracatinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 02 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.